- General Dermatology
- Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
Late Breaking Research: Congenital Ichthyosis
In this video interview, Christopher Bunick, MD, PhD dives into the topic of congenital ichthyosis describing his talk on the skin condition at the American Academy of Dermatology 2022 Annual Meeting.
Patients saw a reduction in scaling and fissuring with TMB-001 (Timber Pharmaceuticals) regardless of the subtype of congenital ichthyosis (CI), according to a presentation at the American Academy of Dermatology's 2022 Annual Meeting.
In a late-breaker presentation and in a subsequent interview with Dermatology Times, Christopher Bunick, MD, PhD, of Yale University, discussed the results of a subanalysis of the phase 2B Control study.
"The medication was quite safe and importantly, there was no significant absorption to the bloodstream, despite [the patients] using it on 73.5% of body surface area.
